ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 2 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $519,483 | -11.0% | 20,332 | -0.1% | 0.00% | – |
| Q2 2023 | $583,925 | +147.1% | 20,360 | +106.5% | 0.00% | – |
| Q1 2023 | $236,343 | +48.6% | 9,860 | +5.2% | 0.00% | – |
| Q4 2022 | $159,016 | +21.4% | 9,376 | +5.8% | 0.00% | – |
| Q3 2022 | $131,000 | -39.9% | 8,861 | -36.1% | 0.00% | – |
| Q2 2022 | $218,000 | -35.7% | 13,871 | +10.4% | 0.00% | – |
| Q1 2022 | $339,000 | -27.1% | 12,566 | 0.0% | 0.00% | – |
| Q4 2021 | $465,000 | +1.8% | 12,566 | +31.2% | 0.00% | – |
| Q3 2021 | $457,000 | +148.4% | 9,581 | +76.6% | 0.00% | – |
| Q2 2021 | $184,000 | -25.5% | 5,426 | -9.3% | 0.00% | – |
| Q1 2021 | $247,000 | -5.7% | 5,982 | -1.0% | 0.00% | – |
| Q4 2020 | $262,000 | +14.4% | 6,045 | +12.8% | 0.00% | – |
| Q3 2020 | $229,000 | -12.6% | 5,357 | -4.2% | 0.00% | – |
| Q2 2020 | $262,000 | – | 5,591 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SEVEN EIGHT CAPITAL, LP | 46,819 | $2,031,000 | 0.47% |
| Orbimed Advisors | 1,206,886 | $49,844,000 | 0.47% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 25,000 | $1,033,000 | 0.40% |
| ARK Investment Management | 3,331,889 | $137,607,000 | 0.27% |
| FEDERATED HERMES, INC. | 3,203,000 | $132,284,000 | 0.26% |
| MGO ONE SEVEN LLC | 26,990 | $1,114,000 | 0.19% |
| Koss-Olinger Consulting, LLC | 20,000 | $826,000 | 0.14% |
| Jump Financial, LLC | 35,400 | $1,462,000 | 0.14% |
| Graham Capital Management, L.P. | 74,262 | $3,067,000 | 0.14% |
| New England Research & Management, Inc. | 6,005 | $248,000 | 0.14% |